MA50354A - Anticorps ciblant le cd137 et leurs méthodes d'utilisation - Google Patents
Anticorps ciblant le cd137 et leurs méthodes d'utilisationInfo
- Publication number
- MA50354A MA50354A MA050354A MA50354A MA50354A MA 50354 A MA50354 A MA 50354A MA 050354 A MA050354 A MA 050354A MA 50354 A MA50354 A MA 50354A MA 50354 A MA50354 A MA 50354A
- Authority
- MA
- Morocco
- Prior art keywords
- methods
- antibodies targeting
- targeting
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17195780.6A EP3470428A1 (en) | 2017-10-10 | 2017-10-10 | Antibodies targeting cd137 and methods of use thereof |
| EP18167092 | 2018-04-12 | ||
| EP18180815 | 2018-06-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA50354A true MA50354A (fr) | 2020-08-19 |
Family
ID=63834023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA050354A MA50354A (fr) | 2017-10-10 | 2018-10-09 | Anticorps ciblant le cd137 et leurs méthodes d'utilisation |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11578133B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3694880A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7438939B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN111183159B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2018348431B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3075337A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL273841B1 (cg-RX-API-DMAC7.html) |
| MA (1) | MA50354A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202003111SA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019072870A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3053803A1 (en) | 2017-02-24 | 2018-08-30 | Macrogenics, Inc. | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof |
| JP7130678B2 (ja) * | 2017-06-05 | 2022-09-05 | ヌマブ セラピューティクス アクチェンゲゼルシャフト | 新規抗ｈｓａ抗体 |
| WO2019072868A1 (en) * | 2017-10-10 | 2019-04-18 | Numab Therapeutics AG | MULTISPECIFIC ANTIBODIES |
| CN112839960B (zh) | 2018-08-10 | 2024-09-06 | 中外制药株式会社 | 抗cd137抗原结合分子及其应用 |
| BR112021026309A2 (pt) * | 2019-06-26 | 2022-06-07 | Ap Biosciences Inc | Anticorpos para ativação de células t |
| WO2021013142A1 (zh) * | 2019-07-22 | 2021-01-28 | 江苏恒瑞医药股份有限公司 | 抗4-1bb抗体、其抗原结合片段及双特异性抗体 |
| CN112898426A (zh) * | 2019-11-19 | 2021-06-04 | 非同（成都）生物科技有限公司 | 人源化4-1bb单克隆抗体及其药物组合物 |
| TWI895351B (zh) * | 2020-02-12 | 2025-09-01 | 日商中外製藥股份有限公司 | 用於癌症之治療的抗cd137抗原結合分子 |
| EP4112642A4 (en) * | 2020-02-28 | 2024-06-26 | Shanghai Henlius Biotech, Inc. | ANTI-CD137 CONSTRUCTION AND ITS USE |
| CN116249555A (zh) | 2020-05-19 | 2023-06-09 | 勃林格殷格翰国际有限公司 | 用于癌症治疗的结合分子 |
| KR20230169135A (ko) * | 2021-03-09 | 2023-12-15 | 젠맵 에이/에스 | 치료에 있어서 cd40 및 cd137에 대한 다중특이 결합제 |
| AU2022339953A1 (en) * | 2021-09-03 | 2024-02-29 | Novarock Biotherapeutics, Ltd. | BISPECIFIC AND TRISPECIFIC BINDING PROTEINS TO PD-L1, CD137, AND/OR TGFβ AND USES THEREOF |
| WO2024240690A2 (en) * | 2023-05-19 | 2024-11-28 | Numab Therapeutics AG | Antibody variable domains and antibodies having decreased immunogenicity |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US5013653A (en) | 1987-03-20 | 1991-05-07 | Creative Biomolecules, Inc. | Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| EP0318554B2 (en) | 1987-05-21 | 2005-01-12 | Micromet AG | Targeted multifunctional proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| EP1291360A1 (en) | 1991-12-13 | 2003-03-12 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| ATE386802T1 (de) | 1997-06-12 | 2008-03-15 | Novartis Int Pharm Ltd | Künstliche antikörperpolypeptide |
| DE19819846B4 (de) | 1998-05-05 | 2016-11-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Multivalente Antikörper-Konstrukte |
| KR20000034847A (ko) * | 1998-11-17 | 2000-06-26 | 성재갑 | 인간 4-1비비 분자에 대한 인간화 항체 및 이를 포함하는 약학조성물 |
| US6887673B2 (en) | 2002-07-30 | 2005-05-03 | Bristol-Myers Squibb Company | Humanized antibodies against human 4-1BB |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| US8921279B2 (en) | 2007-06-26 | 2014-12-30 | F-Star Biotechnologische Forschungs—und Entwicklungsges. m.b.H | Display of binding agents |
| TW202442680A (zh) | 2008-12-09 | 2024-11-01 | 美商建南德克公司 | 抗pd-l1抗體及其於增進t細胞功能之用途 |
| MX343747B (es) | 2009-11-24 | 2016-11-22 | Medimmune Ltd | Agentes de union diana contra b7-h1. |
| DK2614082T3 (en) | 2010-09-09 | 2018-11-26 | Pfizer | 4-1BB BINDING MOLECULES |
| MX349096B (es) | 2011-11-28 | 2017-07-11 | Merck Patent Gmbh | Anticuerpos anti-pd-l1 y sus usos. |
| CN105940014A (zh) * | 2013-10-25 | 2016-09-14 | 努马布有限公司 | 双特异性构造及其在治疗各种疾病中的用途 |
| MA41044A (fr) * | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| MX395604B (es) | 2015-06-15 | 2025-03-25 | Numab Therapeutics AG | Formato de anticuerpo multiespecífico heterodimérico. |
| WO2019072868A1 (en) * | 2017-10-10 | 2019-04-18 | Numab Therapeutics AG | MULTISPECIFIC ANTIBODIES |
-
2018
- 2018-10-09 CA CA3075337A patent/CA3075337A1/en active Pending
- 2018-10-09 WO PCT/EP2018/077514 patent/WO2019072870A1/en not_active Ceased
- 2018-10-09 AU AU2018348431A patent/AU2018348431B2/en active Active
- 2018-10-09 JP JP2020520050A patent/JP7438939B2/ja active Active
- 2018-10-09 EP EP18785593.7A patent/EP3694880A1/en active Pending
- 2018-10-09 US US16/754,097 patent/US11578133B2/en active Active
- 2018-10-09 MA MA050354A patent/MA50354A/fr unknown
- 2018-10-09 CN CN201880065319.9A patent/CN111183159B/zh active Active
- 2018-10-09 SG SG11202003111SA patent/SG11202003111SA/en unknown
-
2020
- 2020-04-06 IL IL273841A patent/IL273841B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP7438939B2 (ja) | 2024-02-27 |
| IL273841B1 (en) | 2025-11-01 |
| KR20200063153A (ko) | 2020-06-04 |
| US20200332015A1 (en) | 2020-10-22 |
| SG11202003111SA (en) | 2020-05-28 |
| AU2018348431B2 (en) | 2025-10-02 |
| JP2020537520A (ja) | 2020-12-24 |
| EP3694880A1 (en) | 2020-08-19 |
| CN111183159B (zh) | 2024-09-03 |
| CN111183159A (zh) | 2020-05-19 |
| CA3075337A1 (en) | 2019-04-18 |
| IL273841A (en) | 2020-05-31 |
| AU2018348431A1 (en) | 2020-03-12 |
| US11578133B2 (en) | 2023-02-14 |
| WO2019072870A1 (en) | 2019-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA50354A (fr) | Anticorps ciblant le cd137 et leurs méthodes d'utilisation | |
| MA50957A (fr) | Anticorps anti-tigit et leurs méthodes d'utilisation | |
| EP3852805A4 (en) | ANTI-LILRB2 ANTIBODIES AND METHODS OF USE THEREOF | |
| MA45123A (fr) | Anticorps anti-tim-3 et leurs méthodes d'utilisation | |
| FR24C1050I2 (fr) | Récepteurs d'antigènes chimériques basés sur des anticorps à domaine unique et leurs méthodes d'utilisation | |
| EP3383430A4 (en) | ANTIBODIES AND METHOD FOR USE THEREOF | |
| EP3525583A4 (en) | ANTI-CS1 ANTIBODIES AND METHOD FOR USE THEREOF | |
| EP3383431A4 (en) | ANTI-GITR ANTIBODIES AND METHOD OF USE THEREOF | |
| EP3700527A4 (en) | PAPD5 INHIBITORS AND METHOD OF USING THEM | |
| MA42925A (fr) | Anticorps anti-tigit et méthodes d'utilisation | |
| MA48462A (fr) | Formulations d'anticorps anti-rankl humains, et leurs méthodes d'utilisation | |
| EP3723803A4 (en) | ANTI-TREM2 ANTIBODIES AND RELATED PROCEDURES | |
| MA48579A (fr) | Anticorps anti-pd1 et méthodes d'utilisation de ceux-ci | |
| MA52459A (fr) | Anticorps se liant spécifiquement à pd-1 et leurs méthodes d'utilisation | |
| MA48595A (fr) | Anticorps anti-tau et leurs méthodes d'utilisation | |
| EP3728323A4 (en) | ANTI-FRIZZLED ANTIBODIES AND METHODS OF USE | |
| MA44955A (fr) | Anticorps anti-tau et leurs méthodes d'utilisation | |
| EP3370770A4 (en) | Subcutaneous formulations of anti-CD38 antibodies and their uses | |
| EP3684819A4 (en) | Anti-ykl40 antibodies and methods of use | |
| MA42243A (fr) | Anticorps de facteur xi et méthodes d'utilisation | |
| EP3383917A4 (en) | Novel anti-claudin antibodies and methods of use | |
| MA46923A (fr) | Compositions à base d'arni ciblant le gène serpina1 et leurs méthodes d'utilisation | |
| MA43282A (fr) | Nouveaux anticorps anti-emr2 et méthodes d'utilisation associées | |
| EP3684369A4 (en) | A33-ANTIBODY COMPOSITIONS AND METHOD OF USING THEREOF IN RADIOIMMUNOTHERAPY | |
| EP3731867A4 (en) | Anti-lrp5/6 antibodies and methods of use |